Document is current
Any future updates will be listed below
-
Authors
Lee, Sul A https://orcid.org/0000-0003-2121-721X
Lafargue, Marie-Camille https://orcid.org/0000-0001-9000-1207
Williams, Winfred W.
Safa, Kassem
Palsson, Ragnar
Al Jurdi, Ayman
Cohen-Bucay, Abraham https://orcid.org/0000-0003-4951-7070
Nissaisorakarn, Pitchaphon https://orcid.org/0000-0002-0245-2954
Gilligan, Hannah
Jüeppner, Harald
Morena, Leela
Borges, Thiago J. https://orcid.org/0000-0002-6554-0169
Le, Mariesa A. https://orcid.org/0000-0002-5220-7228
Joyal, Kayla F.
Rhee, Eugene P. https://orcid.org/0000-0002-4804-7583
Rosales, Ivy https://orcid.org/0000-0003-0621-3202
Brannon, Thomas
Wysocki, Jan
Batlle, Daniel
Kawai, Tatsuo https://orcid.org/0000-0002-6900-4603
Riella, Leonardo V. https://orcid.org/0000-0002-7636-3196
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI143887)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (TL1DK143273)
- License Information
-
More Information
Article History
Received: 8 April 2025
Accepted: 8 August 2025
First Online: 26 September 2025
Competing interests
: The clinical study was supported by Massachusetts General Hospital and eGenesis. The source animal and porcine blood chemistry data were provided in kind by eGenesis. No direct salary or financial incentives were provided to the investigators by eGenesis. L.V.R. has served on scientific advisory boards for Apellis, Sanofi, Calliditas, and Novo Nordisk. D.B. and J.W. are coinventors of patents entitled “Active Low Molecular Weight Variants of Angiotensin Converting Enzyme 2 (ACE2)” and “Soluble ACE2 Variants and Uses Therefor.” D.B. is the founder of Angiotensin Therapeutics Inc. and a main shareholder. The remaining authors declare no competing interests.
